Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.

Gluba-Brzózka A, Michalska-Kasiczak M, Franczyk B, Nocuń M, Toth P, Banach M, Rysz J.

Lipids Health Dis. 2016 Feb 3;15:22. doi: 10.1186/s12944-016-0191-x. Erratum in: Lipids Health Dis. 2016;15(1):62.

2.

Role of osteoprotegerin and its gene polymorphisms in the occurrence of left ventricular hypertrophy in essential hypertensive patients.

Shen A, Hou X, Yang D, Liu T, Zheng D, Deng L, Zhou T.

Medicine (Baltimore). 2014 Dec;93(29):e154. doi: 10.1097/MD.0000000000000154.

3.

Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease.

Nascimento MM, Hayashi SY, Riella MC, Lindholm B.

Braz J Med Biol Res. 2014 Nov;47(11):995-1002. Epub 2014 Aug 22.

4.

TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.

Novoyatleva T, Sajjad A, Engel FB.

Front Immunol. 2014 Feb 11;5:50. doi: 10.3389/fimmu.2014.00050. eCollection 2014. Review.

5.

Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.

Bjerre M.

Springerplus. 2013 Dec 6;2:658. doi: 10.1186/2193-1801-2-658. Review.

6.

Osteoprotegerin and cardiovascular mortality in patients with non-ST elevation acute coronary syndromes.

Røysland R, Bonaca MP, Omland T, Sabatine M, Murphy SA, Scirica BM, Bjerre M, Flyvbjerg A, Braunwald E, Morrow DA.

Heart. 2012 May;98(10):786-91. doi: 10.1136/heartjnl-2011-301260. Epub 2012 Feb 28.

7.

Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease.

Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS; CRIC Study Group.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2612-9. doi: 10.2215/CJN.03910411. Epub 2011 Sep 22.

8.

Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men.

Chen WJ, Rijzewijk LJ, van der Meer RW, Heymans MW, van Duinkerken E, Lubberink M, Lammertsma AA, Lamb HJ, de Roos A, Romijn JA, Smit JW, Bax JJ, Bjerre M, Frystyk J, Flyvbjerg A, Diamant M.

Cardiovasc Diabetol. 2011 Jul 19;10:67. doi: 10.1186/1475-2840-10-67.

9.

Association of serum osteoprotegerin with left ventricular mass in African American adults with hypertension.

Noheria A, Mosley TH Jr, Kullo IJ.

Am J Hypertens. 2010 Jul;23(7):767-74. doi: 10.1038/ajh.2010.59. Epub 2010 Mar 25.

10.

Relation of multiple inflammatory biomarkers to incident atrial fibrillation.

Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, Keaney JF Jr, Wang TJ, Vasan RS, Benjamin EJ.

Am J Cardiol. 2009 Jul 1;104(1):92-6. doi: 10.1016/j.amjcard.2009.02.053. Epub 2009 May 4.

11.

Osteoprotegerin, vascular calcification and atherosclerosis.

Van Campenhout A, Golledge J.

Atherosclerosis. 2009 Jun;204(2):321-9. doi: 10.1016/j.atherosclerosis.2008.09.033. Epub 2008 Oct 9. Review.

Items per page

Supplemental Content

Write to the Help Desk